Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of concomitant treatment of HIV/HCV co-infection with pegylated interferon + ribavirin and lopinavir/ritonavir monotherapy
2007-003544-30Phase 4Active
- Sponsor
- Dr. Ortega: Hospital General de Valencia
- Start
- Nov 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lopinavir, ritonavir, ribavirin and pegylated interferon alpha in human immunodeficiency virus infection (HIV) and hepatitis C virus infection, sponsored by Dr. Ortega: Hospital General de Valencia. Primary endpoints: HCV RNA viral load and HIV RNA viral load. Started Nov 2007; status: active.
02
Drugs
lopinavirritonavirribavirinpegylated interferon alpha
03
Conditions
human immunodeficiency virus infection (HIV)hepatitis C virus infection
Beyond the preview
Go deeper on 2007-003544-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003544-30.